Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection
- 20 April 2018
- journal article
- research article
- Published by Springer Nature in European Radiology
- Vol. 28 (10) , 4265-4273
Abstract
To assess factors associated with radical resection (R0) of pancreatic ductal adenocarcinoma (PDAC) after induction treatment with FOLFIRINOX.Keywords
This publication has 36 references indexed in Scilit:
- Locally Advanced Pancreatic Adenocarcinoma: Reassessment of Response with CT after Neoadjuvant Chemotherapy and Radiation TherapyRadiology, 2014
- Imaging diagnosis of pancreatic cancer: A state-of-the-art reviewWorld Journal of Gastroenterology, 2014
- Pancreatic Ductal AdenocarcinomaAnnals of Surgery, 2013
- Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial DesignAnnals of Surgical Oncology, 2013
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5‐fluorouracil, and cisplatin followed by radiotherapy and 5‐fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinomaJournal of Surgical Oncology, 2010
- Short- and Midterm Reproducibility of Apparent Diffusion Coefficient Measurements at 3.0-T Diffusion-weighted Imaging of the AbdomenRadiology, 2009
- Advanced pancreatic cancer: the use of the apparent diffusion coefficient to predict response to chemotherapyBritish Journal of Radiology, 2009
- Comprehensive Preoperative Assessment of Pancreatic Adenocarcinoma with 64-Section Volumetric CTRadioGraphics, 2007
- Neoadjuvant Chemoradiation for Localized Adenocarcinoma of the PancreasAnnals of Surgical Oncology, 2001